Cara Community Biotechs: Editas

Editas Medicine (NASDAQ: EDIT) reviewed 10-14-2020

Market Cap: $2.0 Billion (USD)   Share Price: $32.16 (USD)

Shares outstanding: 62,103,649

Cash & cash equivalents: $485.8 M (USD) as of 30 Jun 2020

Debt:  None stated on the balance sheet

Insiders: 2.4%                    Institutional: 291 holders own approx. 76% of the float


Investor Presentations:

CEO: Cynthia Collins                        HQs: Cambridge, Mass. USA

Editas Medicine is a gene-editing company that seeks to transform the genome editing system (CRISPR/Cas9 and CRISPR/Cpf1) into a pipeline of medicines to treat serious diseases

CRISPR is a pair of biological “scissors” used to modify genetic code

The two discoverers of CRISPR, Emmanuelle Charpentier (France) and Jennifer Doudna (US) recently received the Nobel Prize for Chemistry (Note: they are not Editas employees)

Editas has a variety of early-stage clinical products:

IN Vivo CRISPR medicines:

  • EDIT-101 – Leber Congenital Amaurosis 10 (LCA10)
  • EDIT-102 – Usher Syndrome 2A (USH2A)
  • Neurological diseases

EX Vivo CRISPR medicines:

  • EDIT-301 – Sickle Cell
  • EDIT-201 – Healthy Donor NK (HDNK) Cells

The company targets ocular diseases, blood diseases, and cancer

Editas reported a loss of $1.12 (USD) for the six months ended 30 Jun 2020

Bottom Line:

  • Editas is a dark horse biotech that has a genome editing platform based on more precise and safer CRISPR technology now into both in vivo and ex vivo clinical trials using their advanced pluripotent cell line

Like to give your opinion? Join our Community Discussion